<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807221</url>
  </required_header>
  <id_info>
    <org_study_id>14564</org_study_id>
    <secondary_id>2012-002627-15</secondary_id>
    <nct_id>NCT01807221</nct_id>
  </id_info>
  <brief_title>Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</brief_title>
  <acronym>ARTS-HF</acronym>
  <official_title>A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was&#xD;
      safe and can help the well-being of patients with worsening chronic heart failure and either&#xD;
      type II diabetes with or without chronic kidney disease or kidney disease alone. These&#xD;
      treatment doses were compared to eplerenone, another marketed drug approved to treat heart&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2013</start_date>
  <completion_date type="Actual">December 9, 2014</completion_date>
  <primary_completion_date type="Actual">November 11, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
    <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death Due to Any Cause</measure>
    <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Hospitalization</measure>
    <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)</measure>
    <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of BNP at Specified Visits to BNP at Baseline</measure>
    <time_frame>Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline</measure>
    <time_frame>Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ Questionnaire Scores at Specified Visits</measure>
    <time_frame>Baseline, Day 30 and Day 90</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits</measure>
    <time_frame>Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
    <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Serum Potassium at Specified Visits</measure>
    <time_frame>Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Specified Visits</measure>
    <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Specified Visits</measure>
    <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Heart Rate at Specified Visits</measure>
    <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1066</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Finerenone(BAY94-8862)[2.5mg] + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)[5mg] + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)[7.5mg] + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)[10mg] + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (BAY94-8862)[15mg] + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone [25 mg] + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY94-8862)</intervention_name>
    <arm_group_label>Finerenone (BAY94-8862)[10mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[15mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[5mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[7.5mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone(BAY94-8862)[2.5mg] + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Eplerenone [25 mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[10mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[15mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[5mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone (BAY94-8862)[7.5mg] + Placebo</arm_group_label>
    <arm_group_label>Finerenone(BAY94-8862)[2.5mg] + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inspra (eplerenone)</intervention_name>
    <arm_group_label>Eplerenone [25 mg] + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 years and older. The lower age limit may be higher if legally&#xD;
             required in the participating country&#xD;
&#xD;
          -  Women of childbearing potential can only be included in the study if a pregnancy test&#xD;
             is negative and if they agree to use adequate contraception when sexually active&#xD;
&#xD;
          -  Subjects with worsening chronic heart failure requiring emergency presentation to&#xD;
             hospital and treatment with intravenous diuretics at hospital&#xD;
&#xD;
          -  Subjects with clinical diagnosis of chronic heart failure (CHF) either ischemic or non&#xD;
             ischemic, New York Heart Association (NYHA) functional class II-IV&#xD;
&#xD;
          -  Subjects with type 2 diabetes mellitus and / or&#xD;
&#xD;
          -  Subjects with 30 mL/min/1.73m^2 &lt;/= eGFR &lt;/= 60 mL/min/1.73m^2 (MDRD, Modification of&#xD;
             Diet in Renal Disease Study Group) at screening&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;/= 40%&#xD;
&#xD;
          -  Blood potassium &lt;/= 5.0 mmol/L at screening&#xD;
&#xD;
          -  Systolic blood pressure &gt;/= 90 mmHg without signs and symptoms of hypotension at the&#xD;
             screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute de-novo heart failure or acute inflammatory heart disease, e.g. acute&#xD;
             myocarditis&#xD;
&#xD;
          -  Acute coronary syndrome (ACS) in last 30 days prior to screening&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Valvular heart disease requiring surgical intervention during the course of the study&#xD;
&#xD;
          -  Stroke or transient ischemic cerebral attack in the last 3 months prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  Concomitant treatment with any mineralocorticoid receptor antagonist (MRA), renin&#xD;
             inhibitor, or potassium-sparing diuretic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krems an der Donau</city>
        <state>Niederösterreich</state>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgas</city>
        <zip>8018</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Jean-sur-Richelieu</city>
        <state>Quebec</state>
        <zip>J3A 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>728 80</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>02740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00099</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rovaniemi</city>
        <zip>96101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>PARIS cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris cedex 13</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limburg</city>
        <state>Hessen</state>
        <zip>65549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaidari</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nea Ionia / Athens</city>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadera</city>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <zip>2210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <zip>1311001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerifin</city>
        <zip>7030000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza Brianza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52040</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <state>Gang''weondo</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>LT-44320</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>LT-47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>70-965</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>P-4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isipingo Rail</city>
        <state>Kwazulu-Natal</state>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merebank</city>
        <state>Kwazulu-Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tongaat</city>
        <state>Kwazulu-Natal</state>
        <zip>4400</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuils River</city>
        <state>Western Cape</state>
        <zip>7580</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinelands</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olot</city>
        <state>Girona</state>
        <zip>17800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taizung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antalya</city>
        <zip>07003</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <results_reference>
    <citation>Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29.</citation>
    <PMID>27130705</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10:CD007004. doi: 10.1002/14651858.CD007004.pub4.</citation>
    <PMID>33107592</PMID>
  </results_reference>
  <results_reference>
    <citation>Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.</citation>
    <PMID>25678098</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>April 15, 2021</results_first_submitted>
  <results_first_submitted_qc>May 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2021</results_first_posted>
  <disposition_first_submitted>June 4, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 1, 2015</disposition_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Decompensation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted in 168 study centers in 25 countries worldwide, from 17 June 2013 (first participant first visit) to 09 December 2014 (last participant last visit).</recruitment_details>
      <pre_assignment_details>Out of 1286 screened participants, 1066 participants were randomized, 1055 participants received study treatment and were valid for safety analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eplerenone (INSPRA®)</title>
          <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
        </group>
        <group group_id="P2">
          <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
          <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="P3">
          <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
          <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="P4">
          <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
          <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="P5">
          <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
          <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="P6">
          <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
          <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="169"/>
                <participants group_id="P5" count="170"/>
                <participants group_id="P6" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Study Treatment and Valid for Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="172"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="169"/>
                <participants group_id="P6" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="134"/>
                <participants group_id="P6" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Logistical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set (SAF): all randomized participants who took at least one dose of study drug and with data after beginning of treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Eplerenone (INSPRA®)</title>
          <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B2">
          <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
          <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B3">
          <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
          <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B4">
          <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
          <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B5">
          <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
          <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B6">
          <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
          <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="172"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="167"/>
            <count group_id="B5" value="169"/>
            <count group_id="B6" value="163"/>
            <count group_id="B7" value="1055"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="172"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="167"/>
                    <count group_id="B5" value="169"/>
                    <count group_id="B6" value="163"/>
                    <count group_id="B7" value="1055"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.38" spread="9.92"/>
                    <measurement group_id="B2" value="72.53" spread="9.74"/>
                    <measurement group_id="B3" value="71.81" spread="10.55"/>
                    <measurement group_id="B4" value="69.27" spread="9.83"/>
                    <measurement group_id="B5" value="71.27" spread="10.27"/>
                    <measurement group_id="B6" value="69.2" spread="10.15"/>
                    <measurement group_id="B7" value="71.15" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="221"/>
                    <count group_id="B2" value="172"/>
                    <count group_id="B3" value="163"/>
                    <count group_id="B4" value="167"/>
                    <count group_id="B5" value="169"/>
                    <count group_id="B6" value="163"/>
                    <count group_id="B7" value="1055"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="128"/>
                    <measurement group_id="B6" value="132"/>
                    <measurement group_id="B7" value="815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline BNP</title>
          <description>B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
          <population>Participants with valid data for this baseline characteristic</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="203"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="151"/>
                    <count group_id="B4" value="156"/>
                    <count group_id="B5" value="158"/>
                    <count group_id="B6" value="155"/>
                    <count group_id="B7" value="979"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="594.290" spread="2.601"/>
                    <measurement group_id="B2" value="677.906" spread="2.637"/>
                    <measurement group_id="B3" value="574.245" spread="2.543"/>
                    <measurement group_id="B4" value="570.776" spread="2.741"/>
                    <measurement group_id="B5" value="606.080" spread="2.598"/>
                    <measurement group_id="B6" value="552.032" spread="2.698"/>
                    <measurement group_id="B7" value="594.732" spread="2.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline NT-proBNP</title>
          <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
          <population>Participants with valid data for this baseline characteristic</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="207"/>
                    <count group_id="B2" value="162"/>
                    <count group_id="B3" value="157"/>
                    <count group_id="B4" value="158"/>
                    <count group_id="B5" value="160"/>
                    <count group_id="B6" value="158"/>
                    <count group_id="B7" value="1002"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4730.170" spread="2.938"/>
                    <measurement group_id="B2" value="4793.430" spread="3.084"/>
                    <measurement group_id="B3" value="4184.631" spread="3.093"/>
                    <measurement group_id="B4" value="3776.859" spread="3.395"/>
                    <measurement group_id="B5" value="4163.898" spread="2.734"/>
                    <measurement group_id="B6" value="3791.677" spread="3.013"/>
                    <measurement group_id="B7" value="4246.883" spread="3.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90</title>
        <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
        <time_frame>Baseline and Day 90</time_frame>
        <population>Full analysis set (FAS): all participants who the study drug, had baseline and at least one post-baseline NT-proBNP value or who died or experienced permanent (≥5 consecutive days) withdrawal of study drug after cardiovascular (CV) hospitalization or after emergency presentation for Worsening Chronic Heart Failure (WCHF)</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90</title>
          <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
          <population>Full analysis set (FAS): all participants who the study drug, had baseline and at least one post-baseline NT-proBNP value or who died or experienced permanent (≥5 consecutive days) withdrawal of study drug after cardiovascular (CV) hospitalization or after emergency presentation for Worsening Chronic Heart Failure (WCHF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="31.6" lower_limit="31.6" upper_limit="43.1"/>
                    <measurement group_id="O2" value="30.9" spread="24.9" lower_limit="24.9" upper_limit="37.4"/>
                    <measurement group_id="O3" value="32.5" spread="26.3" lower_limit="26.3" upper_limit="39.2"/>
                    <measurement group_id="O4" value="37.3" spread="30.9" lower_limit="30.9" upper_limit="44.1"/>
                    <measurement group_id="O5" value="38.8" spread="32.3" lower_limit="32.3" upper_limit="45.5"/>
                    <measurement group_id="O6" value="34.2" spread="27.9" lower_limit="27.9" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimates and two-sided 90% confidence intervals are provided for each treatment group and for the treatment differences πBi - πC. Clopper-Pearson confidence intervals were calculated for each treatment group, while for treatment differences the exact unconditional confidence limits were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8771</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Estimates and two-sided 90% confidence intervals are provided for each treatment group and for the treatment differences πBi - πC. Clopper-Pearson confidence intervals were calculated for each treatment group, while for treatment differences the exact unconditional confidence limits were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7945</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimates and two-sided 90% confidence intervals are provided for each treatment group and for the treatment differences πBi - πC. Clopper-Pearsonconfidence intervals were calculated for each treatment group, while for treatment differences the exact unconditional confidence limits were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Estimates and two-sided 90% confidence intervals are provided for each treatment group and for the treatment differences πBi - πC. Clopper-Pearsonconfidence intervals were calculated for each treatment group, while for treatment differences the exact unconditional confidence limits were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4225</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Estimates and two-sided 90% confidence intervals are provided for each treatment group and for the treatment differences πBi - πC. Clopper-Pearson confidence intervals were calculated for each treatment group, while for treatment differences the exact unconditional confidence limits were calculated.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6865</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death Due to Any Cause</title>
        <description>Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes.</description>
        <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death Due to Any Cause</title>
          <description>Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes.</description>
          <population>Participants in FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Hospitalization</title>
        <description>Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations.</description>
        <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Hospitalization</title>
          <description>Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations.</description>
          <population>Participants in FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)</title>
        <description>Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents.</description>
        <time_frame>Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)</title>
          <description>Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents.</description>
          <population>Participants in FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of BNP at Specified Visits to BNP at Baseline</title>
        <description>B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
        <time_frame>Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of BNP at Specified Visits to BNP at Baseline</title>
          <description>B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
          <population>Participants in FAS with valid data at specified visits</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.925" spread="2.02"/>
                    <measurement group_id="O2" value="0.944" spread="1.952"/>
                    <measurement group_id="O3" value="0.878" spread="1.713"/>
                    <measurement group_id="O4" value="0.832" spread="1.959"/>
                    <measurement group_id="O5" value="0.852" spread="1.901"/>
                    <measurement group_id="O6" value="0.879" spread="1.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="133"/>
                    <count group_id="O6" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.783" spread="2.194"/>
                    <measurement group_id="O2" value="0.864" spread="2.139"/>
                    <measurement group_id="O3" value="0.854" spread="1.854"/>
                    <measurement group_id="O4" value="0.79" spread="2.179"/>
                    <measurement group_id="O5" value="0.711" spread="2.116"/>
                    <measurement group_id="O6" value="0.824" spread="2.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="127"/>
                    <count group_id="O6" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.723" spread="2.202"/>
                    <measurement group_id="O2" value="0.813" spread="2.412"/>
                    <measurement group_id="O3" value="0.839" spread="1.93"/>
                    <measurement group_id="O4" value="0.719" spread="2.204"/>
                    <measurement group_id="O5" value="0.706" spread="2.34"/>
                    <measurement group_id="O6" value="0.771" spread="2.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.896" spread="0.896"/>
                    <measurement group_id="O2" value="1.104" spread="2.15"/>
                    <measurement group_id="O3" value="1.006" spread="2.422"/>
                    <measurement group_id="O4" value="0.884" spread="1.973"/>
                    <measurement group_id="O5" value="0.848" spread="2.218"/>
                    <measurement group_id="O6" value="1.044" spread="2.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="143"/>
                    <count group_id="O6" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.795" spread="2.232"/>
                    <measurement group_id="O2" value="0.815" spread="2.388"/>
                    <measurement group_id="O3" value="0.886" spread="2.199"/>
                    <measurement group_id="O4" value="0.726" spread="2.397"/>
                    <measurement group_id="O5" value="0.729" spread="2.487"/>
                    <measurement group_id="O6" value="0.852" spread="2.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline</title>
        <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
        <time_frame>Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline</title>
          <description>N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.</description>
          <population>Participants in FAS with valid data at specified visits</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.883" spread="2.458"/>
                    <measurement group_id="O2" value="0.98" spread="2.158"/>
                    <measurement group_id="O3" value="0.874" spread="2.14"/>
                    <measurement group_id="O4" value="0.888" spread="2.123"/>
                    <measurement group_id="O5" value="0.822" spread="2.217"/>
                    <measurement group_id="O6" value="0.921" spread="2.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.749" spread="2.73"/>
                    <measurement group_id="O2" value="0.822" spread="2.423"/>
                    <measurement group_id="O3" value="0.814" spread="2.178"/>
                    <measurement group_id="O4" value="0.81" spread="2.268"/>
                    <measurement group_id="O5" value="0.748" spread="2.496"/>
                    <measurement group_id="O6" value="0.829" spread="2.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="118"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.688" spread="2.59"/>
                    <measurement group_id="O2" value="0.789" spread="2.661"/>
                    <measurement group_id="O3" value="0.765" spread="2.214"/>
                    <measurement group_id="O4" value="0.783" spread="2.454"/>
                    <measurement group_id="O5" value="0.728" spread="2.795"/>
                    <measurement group_id="O6" value="0.771" spread="2.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" spread="2.684"/>
                    <measurement group_id="O2" value="1.369" spread="2.087"/>
                    <measurement group_id="O3" value="1.267" spread="2.261"/>
                    <measurement group_id="O4" value="0.927" spread="1.864"/>
                    <measurement group_id="O5" value="1.133" spread="2.981"/>
                    <measurement group_id="O6" value="0.965" spread="2.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.747" spread="2.616"/>
                    <measurement group_id="O2" value="0.747" spread="2.741"/>
                    <measurement group_id="O3" value="0.887" spread="2.604"/>
                    <measurement group_id="O4" value="0.809" spread="2.647"/>
                    <measurement group_id="O5" value="0.746" spread="2.472"/>
                    <measurement group_id="O6" value="0.849" spread="2.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ Questionnaire Scores at Specified Visits</title>
        <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points.</description>
        <time_frame>Baseline, Day 30 and Day 90</time_frame>
        <population>Participants in FAS with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ Questionnaire Scores at Specified Visits</title>
          <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points.</description>
          <population>Participants in FAS with valid data at specified visits</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="161"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="158"/>
                    <count group_id="O5" value="160"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="23"/>
                    <measurement group_id="O2" value="42.8" spread="22.6"/>
                    <measurement group_id="O3" value="45.4" spread="24"/>
                    <measurement group_id="O4" value="42.1" spread="23.2"/>
                    <measurement group_id="O5" value="42.3" spread="23.7"/>
                    <measurement group_id="O6" value="43.2" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="141"/>
                    <count group_id="O6" value="141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="26.2"/>
                    <measurement group_id="O2" value="18.2" spread="22.7"/>
                    <measurement group_id="O3" value="19.3" spread="26.5"/>
                    <measurement group_id="O4" value="23" spread="24.4"/>
                    <measurement group_id="O5" value="24.9" spread="22.9"/>
                    <measurement group_id="O6" value="20.6" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="118"/>
                    <count group_id="O5" value="129"/>
                    <count group_id="O6" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="27.6"/>
                    <measurement group_id="O2" value="21.3" spread="27.2"/>
                    <measurement group_id="O3" value="24.5" spread="27"/>
                    <measurement group_id="O4" value="29.3" spread="28.6"/>
                    <measurement group_id="O5" value="28.3" spread="23.8"/>
                    <measurement group_id="O6" value="22.2" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits</title>
        <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
        <time_frame>Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in FAS with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits</title>
          <description>EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
          <population>Participants in FAS with valid data at specified visits</population>
          <units>Scores on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
                <count group_id="O6" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="157"/>
                    <count group_id="O5" value="158"/>
                    <count group_id="O6" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.25"/>
                    <measurement group_id="O2" value="0.59" spread="0.25"/>
                    <measurement group_id="O3" value="0.62" spread="0.23"/>
                    <measurement group_id="O4" value="0.58" spread="0.23"/>
                    <measurement group_id="O5" value="0.56" spread="0.25"/>
                    <measurement group_id="O6" value="0.59" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="143"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.23"/>
                    <measurement group_id="O2" value="0.02" spread="0.24"/>
                    <measurement group_id="O3" value="0.02" spread="0.23"/>
                    <measurement group_id="O4" value="0.07" spread="0.22"/>
                    <measurement group_id="O5" value="0.06" spread="0.23"/>
                    <measurement group_id="O6" value="0.02" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="117"/>
                    <count group_id="O5" value="126"/>
                    <count group_id="O6" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.24"/>
                    <measurement group_id="O2" value="0.03" spread="0.27"/>
                    <measurement group_id="O3" value="0.04" spread="0.25"/>
                    <measurement group_id="O4" value="0.08" spread="0.2"/>
                    <measurement group_id="O5" value="0.1" spread="0.24"/>
                    <measurement group_id="O6" value="0.06" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.25"/>
                    <measurement group_id="O2" value="-0.06" spread="0.29"/>
                    <measurement group_id="O3" value="-0.09" spread="0.24"/>
                    <measurement group_id="O4" value="-0.1" spread="0.24"/>
                    <measurement group_id="O5" value="-0.05" spread="0.25"/>
                    <measurement group_id="O6" value="0" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="133"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.26"/>
                    <measurement group_id="O2" value="0.01" spread="0.25"/>
                    <measurement group_id="O3" value="0.01" spread="0.27"/>
                    <measurement group_id="O4" value="0.08" spread="0.23"/>
                    <measurement group_id="O5" value="0.07" spread="0.23"/>
                    <measurement group_id="O6" value="0.04" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Serum Potassium at Specified Visits</title>
        <time_frame>Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in SAF with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Potassium at Specified Visits</title>
          <population>Participants in SAF with valid data at specified visits</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="168"/>
                <count group_id="O6" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="162"/>
                    <count group_id="O4" value="167"/>
                    <count group_id="O5" value="168"/>
                    <count group_id="O6" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.159" spread="0.495"/>
                    <measurement group_id="O2" value="4.081" spread="0.501"/>
                    <measurement group_id="O3" value="4.211" spread="0.541"/>
                    <measurement group_id="O4" value="4.174" spread="0.443"/>
                    <measurement group_id="O5" value="4.131" spread="0.506"/>
                    <measurement group_id="O6" value="4.117" spread="0.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="142"/>
                    <count group_id="O5" value="143"/>
                    <count group_id="O6" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.608"/>
                    <measurement group_id="O2" value="0.135" spread="0.573"/>
                    <measurement group_id="O3" value="0.075" spread="0.523"/>
                    <measurement group_id="O4" value="0.085" spread="0.475"/>
                    <measurement group_id="O5" value="0.21" spread="0.592"/>
                    <measurement group_id="O6" value="0.193" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="129"/>
                    <count group_id="O5" value="134"/>
                    <count group_id="O6" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" spread="0.589"/>
                    <measurement group_id="O2" value="0.091" spread="0.568"/>
                    <measurement group_id="O3" value="0.131" spread="0.566"/>
                    <measurement group_id="O4" value="0.171" spread="0.54"/>
                    <measurement group_id="O5" value="0.274" spread="0.522"/>
                    <measurement group_id="O6" value="0.216" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="121"/>
                    <count group_id="O5" value="128"/>
                    <count group_id="O6" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.307" spread="0.609"/>
                    <measurement group_id="O2" value="0.184" spread="0.574"/>
                    <measurement group_id="O3" value="0.153" spread="0.516"/>
                    <measurement group_id="O4" value="0.164" spread="0.579"/>
                    <measurement group_id="O5" value="0.275" spread="0.58"/>
                    <measurement group_id="O6" value="0.245" spread="0.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="139"/>
                    <count group_id="O4" value="134"/>
                    <count group_id="O5" value="145"/>
                    <count group_id="O6" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.621"/>
                    <measurement group_id="O2" value="0.226" spread="0.694"/>
                    <measurement group_id="O3" value="0.054" spread="0.623"/>
                    <measurement group_id="O4" value="0.05" spread="0.572"/>
                    <measurement group_id="O5" value="0.175" spread="0.559"/>
                    <measurement group_id="O6" value="0.036" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Systolic Blood Pressure at Specified Visits</title>
        <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in SAF with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Specified Visits</title>
          <population>Participants in SAF with valid data at specified visits</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="169"/>
                    <count group_id="O6" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.554" spread="18.706"/>
                    <measurement group_id="O2" value="119.492" spread="16.348"/>
                    <measurement group_id="O3" value="118.498" spread="14.355"/>
                    <measurement group_id="O4" value="119.087" spread="16.677"/>
                    <measurement group_id="O5" value="116.024" spread="16.895"/>
                    <measurement group_id="O6" value="116.941" spread="16.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                    <count group_id="O4" value="158"/>
                    <count group_id="O5" value="163"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.541" spread="13.894"/>
                    <measurement group_id="O2" value="-3.178" spread="13.72"/>
                    <measurement group_id="O3" value="-2.565" spread="12.278"/>
                    <measurement group_id="O4" value="0.568" spread="12.733"/>
                    <measurement group_id="O5" value="0.162" spread="15.416"/>
                    <measurement group_id="O6" value="-0.546" spread="13.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.442" spread="14.258"/>
                    <measurement group_id="O2" value="-4.488" spread="10.31"/>
                    <measurement group_id="O3" value="4.142" spread="15.001"/>
                    <measurement group_id="O4" value="1.241" spread="13.561"/>
                    <measurement group_id="O5" value="-3.099" spread="12.591"/>
                    <measurement group_id="O6" value="-2.906" spread="15.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="147"/>
                    <count group_id="O5" value="145"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="15.312"/>
                    <measurement group_id="O2" value="-0.824" spread="15.747"/>
                    <measurement group_id="O3" value="-0.367" spread="14.984"/>
                    <measurement group_id="O4" value="0.374" spread="14.433"/>
                    <measurement group_id="O5" value="1.786" spread="15.039"/>
                    <measurement group_id="O6" value="0.899" spread="14.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="129"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.684" spread="16.315"/>
                    <measurement group_id="O2" value="0.337" spread="14.176"/>
                    <measurement group_id="O3" value="-1.249" spread="13.659"/>
                    <measurement group_id="O4" value="-1.811" spread="14.462"/>
                    <measurement group_id="O5" value="0.981" spread="15.525"/>
                    <measurement group_id="O6" value="0.667" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="121"/>
                    <count group_id="O5" value="131"/>
                    <count group_id="O6" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.967" spread="16.408"/>
                    <measurement group_id="O2" value="0.922" spread="15.847"/>
                    <measurement group_id="O3" value="0.047" spread="15.643"/>
                    <measurement group_id="O4" value="-0.664" spread="15.018"/>
                    <measurement group_id="O5" value="1.216" spread="17.831"/>
                    <measurement group_id="O6" value="0.956" spread="15.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.991" spread="16.456"/>
                    <measurement group_id="O2" value="-0.41" spread="13.936"/>
                    <measurement group_id="O3" value="-2.167" spread="19.963"/>
                    <measurement group_id="O4" value="9.391" spread="22.378"/>
                    <measurement group_id="O5" value="-2.32" spread="11.963"/>
                    <measurement group_id="O6" value="-0.028" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="153"/>
                    <count group_id="O6" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" spread="16.751"/>
                    <measurement group_id="O2" value="2.869" spread="15.502"/>
                    <measurement group_id="O3" value="1.95" spread="16.148"/>
                    <measurement group_id="O4" value="-0.928" spread="17.953"/>
                    <measurement group_id="O5" value="2.041" spread="16.189"/>
                    <measurement group_id="O6" value="3.037" spread="16.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Specified Visits</title>
        <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in SAF with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Specified Visits</title>
          <population>Participants in SAF with valid data at specified visits</population>
          <units>millimeter for mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="169"/>
                    <count group_id="O6" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.633" spread="11.647"/>
                    <measurement group_id="O2" value="71.044" spread="10.762"/>
                    <measurement group_id="O3" value="71.442" spread="8.508"/>
                    <measurement group_id="O4" value="70.61" spread="9.692"/>
                    <measurement group_id="O5" value="70.343" spread="10.394"/>
                    <measurement group_id="O6" value="71.145" spread="9.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="154"/>
                    <count group_id="O4" value="158"/>
                    <count group_id="O5" value="163"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.351" spread="10.237"/>
                    <measurement group_id="O2" value="-1.693" spread="9.911"/>
                    <measurement group_id="O3" value="-2.143" spread="9.848"/>
                    <measurement group_id="O4" value="0.013" spread="9.733"/>
                    <measurement group_id="O5" value="-0.738" spread="10.534"/>
                    <measurement group_id="O6" value="-1.166" spread="8.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.442" spread="10.089"/>
                    <measurement group_id="O2" value="-0.537" spread="9.59"/>
                    <measurement group_id="O3" value="1.608" spread="9.423"/>
                    <measurement group_id="O4" value="-0.083" spread="7.421"/>
                    <measurement group_id="O5" value="-2.387" spread="10.51"/>
                    <measurement group_id="O6" value="-0.625" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="147"/>
                    <count group_id="O5" value="145"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.503" spread="10.826"/>
                    <measurement group_id="O2" value="0.146" spread="10.667"/>
                    <measurement group_id="O3" value="-0.845" spread="8.91"/>
                    <measurement group_id="O4" value="-0.068" spread="9.633"/>
                    <measurement group_id="O5" value="-0.094" spread="10.086"/>
                    <measurement group_id="O6" value="-1.163" spread="9.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="129"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.613" spread="11.096"/>
                    <measurement group_id="O2" value="-0.199" spread="11.297"/>
                    <measurement group_id="O3" value="-2.144" spread="9.552"/>
                    <measurement group_id="O4" value="-0.85" spread="10.472"/>
                    <measurement group_id="O5" value="0.17" spread="10.312"/>
                    <measurement group_id="O6" value="-0.575" spread="10.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="121"/>
                    <count group_id="O5" value="131"/>
                    <count group_id="O6" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.716" spread="11.035"/>
                    <measurement group_id="O2" value="-0.106" spread="11.148"/>
                    <measurement group_id="O3" value="-1.738" spread="9.015"/>
                    <measurement group_id="O4" value="-1.121" spread="9.96"/>
                    <measurement group_id="O5" value="-0.545" spread="11.212"/>
                    <measurement group_id="O6" value="-0.877" spread="11.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.185" spread="11.853"/>
                    <measurement group_id="O2" value="0.868" spread="9.239"/>
                    <measurement group_id="O3" value="-2.194" spread="15.522"/>
                    <measurement group_id="O4" value="4.101" spread="12.151"/>
                    <measurement group_id="O5" value="-2.96" spread="9.199"/>
                    <measurement group_id="O6" value="-0.083" spread="10.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="153"/>
                    <count group_id="O6" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.218" spread="11.477"/>
                    <measurement group_id="O2" value="0.696" spread="13.172"/>
                    <measurement group_id="O3" value="-0.444" spread="10.197"/>
                    <measurement group_id="O4" value="-1.16" spread="11.114"/>
                    <measurement group_id="O5" value="-0.298" spread="11.521"/>
                    <measurement group_id="O6" value="-0.172" spread="10.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Heart Rate at Specified Visits</title>
        <time_frame>Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)</time_frame>
        <population>Participants in SAF with valid data at specified visits</population>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone (INSPRA®)</title>
            <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Finerenone (BAY94-8862) 2.5-5 mg OD</title>
            <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O3">
            <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
            <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O4">
            <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
            <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O5">
            <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
            <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
          <group group_id="O6">
            <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
            <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Specified Visits</title>
          <population>Participants in SAF with valid data at specified visits</population>
          <units>Beats per minute (Beats/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="169"/>
                    <count group_id="O6" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.957" spread="13.813"/>
                    <measurement group_id="O2" value="73.369" spread="13.396"/>
                    <measurement group_id="O3" value="72.681" spread="12.623"/>
                    <measurement group_id="O4" value="74.184" spread="12.369"/>
                    <measurement group_id="O5" value="73.852" spread="11.999"/>
                    <measurement group_id="O6" value="74.329" spread="13.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="153"/>
                    <count group_id="O4" value="158"/>
                    <count group_id="O5" value="163"/>
                    <count group_id="O6" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="10.751"/>
                    <measurement group_id="O2" value="1.073" spread="13.5"/>
                    <measurement group_id="O3" value="-0.63" spread="11.696"/>
                    <measurement group_id="O4" value="-0.719" spread="10.77"/>
                    <measurement group_id="O5" value="-0.548" spread="11.144"/>
                    <measurement group_id="O6" value="-1.176" spread="13.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.109" spread="15.101"/>
                    <measurement group_id="O2" value="0.599" spread="16.387"/>
                    <measurement group_id="O3" value="1.842" spread="14.988"/>
                    <measurement group_id="O4" value="-1.324" spread="13.666"/>
                    <measurement group_id="O5" value="0.423" spread="11.247"/>
                    <measurement group_id="O6" value="-3.969" spread="13.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="147"/>
                    <count group_id="O5" value="145"/>
                    <count group_id="O6" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.294" spread="13.61"/>
                    <measurement group_id="O2" value="1.064" spread="14.128"/>
                    <measurement group_id="O3" value="0.435" spread="13.63"/>
                    <measurement group_id="O4" value="-0.349" spread="12.636"/>
                    <measurement group_id="O5" value="-0.802" spread="11.311"/>
                    <measurement group_id="O6" value="-1.633" spread="12.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="129"/>
                    <count group_id="O5" value="139"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.297" spread="13.033"/>
                    <measurement group_id="O2" value="-0.975" spread="14.953"/>
                    <measurement group_id="O3" value="-1.741" spread="10.86"/>
                    <measurement group_id="O4" value="-2.318" spread="14.225"/>
                    <measurement group_id="O5" value="0.192" spread="13.377"/>
                    <measurement group_id="O6" value="-1.608" spread="13.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="121"/>
                    <count group_id="O5" value="131"/>
                    <count group_id="O6" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.189" spread="12.289"/>
                    <measurement group_id="O2" value="-1.647" spread="13.001"/>
                    <measurement group_id="O3" value="-2.89" spread="12.034"/>
                    <measurement group_id="O4" value="-2.212" spread="12.041"/>
                    <measurement group_id="O5" value="-0.71" spread="13.777"/>
                    <measurement group_id="O6" value="-1.145" spread="14.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.278" spread="15.909"/>
                    <measurement group_id="O2" value="-1.424" spread="15.587"/>
                    <measurement group_id="O3" value="-0.222" spread="7.591"/>
                    <measurement group_id="O4" value="1.101" spread="10.22"/>
                    <measurement group_id="O5" value="4.733" spread="13.646"/>
                    <measurement group_id="O6" value="-2.072" spread="19.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="153"/>
                    <count group_id="O6" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.281" spread="13.789"/>
                    <measurement group_id="O2" value="-2.057" spread="13.982"/>
                    <measurement group_id="O3" value="-0.626" spread="14.196"/>
                    <measurement group_id="O4" value="-1.326" spread="15.488"/>
                    <measurement group_id="O5" value="0.834" spread="14.159"/>
                    <measurement group_id="O6" value="-1.317" spread="14.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events: from the start of study treatment until 3 days post-last dose, up to approximately 93 days. All Cause Mortality: assessed until 30 days post-last dose, up to approximately 120 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eplerenone (INSPRA®)</title>
          <description>Eplerenone 25 milligram (mg) capsule every other day (EOD), on Day 1, Day 3, Day 5, etc, along with placebo capsule (matched to Eplerenone capsule) on Day 2, Day 4, Day 6, etc., and placebo tablet (matched to Finerenone tablet) once daily (OD).The dose could be increased to 25 mg OD at Day 30 and to 50 mg OD at Day 60 (or 25 mg OD if no up-titration occurred on Day 30) if both up-titration steps were performed. Treatment duration was for 90 days.</description>
        </group>
        <group group_id="E2">
          <title>Finerenone(BAY94-8862) 2.5-5 mg OD</title>
          <description>Finerenone 2.5 mg immediate-release (IR) tablets OD and placebo-matched to Eplerenone capsule OD, with possible up-titration to 5 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="E3">
          <title>Finerenone (BAY94-8862) 5-10 mg OD</title>
          <description>Finerenone 5 mg IR tablets OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 10 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="E4">
          <title>Finerenone (BAY94-8862) 7.5-15 mg OD</title>
          <description>Finerenone 7.5 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 15 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="E5">
          <title>Finerenone (BAY94-8862) 10-20 mg OD</title>
          <description>Finerenone 10 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
        <group group_id="E6">
          <title>Finerenone (BAY94-8862) 15-20 mg OD</title>
          <description>Finerenone 15 mg IR tablet OD and placebo capsule (matched to Eplerenone capsule) OD, with possible up-titration to 20 mg OD at Day 30 (Day 30±2) and sham up-titration at Day 60 (Day 60±2). Treatment duration was for 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="169"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="221"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="172"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E4" events="33" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E6" events="14" subjects_affected="13" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="172"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E6" events="16" subjects_affected="12" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="7" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Oedema due to cardiac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Implant site ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abdomen abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular assist device insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac rehabilitation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="169"/>
                <counts group_id="E6" subjects_affected="65" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="172"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="34" subjects_at_risk="221"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="172"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="163"/>
                <counts group_id="E4" events="30" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E6" events="20" subjects_affected="17" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="172"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="172"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer HealthCare AG</organization>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

